ABOUT / Regulatory status
Product development status
Our innovative breath-based cancer detection test is constantly under development and validation and has shown promising results in a large-scale observational clinical trial.

The SpotitEarly tests have not been approved yet by the Food and Drug Administration (FDA) and are currently under development and validation.
We are actively pursuing regulatory approval to bring this solution to a commercial phase.
Our follow-up clinical studies, the Pink study and the White study, offer additional substantial clinical validation for the product and method we employ. These meticulously designed and executed studies build upon the foundation of our initial research, further solidifying the efficacy and safety of our product.
Our CLIA-certified laboratory is equipped with state-of-the-art technology and staffed by highly trained and experienced professionals. We follow strict protocols to ensure that our tests are performed accurately and reliably.